AVIR Stock Analysis: Buy, Sell, or Hold?
AVIR - Atea Pharmaceuticals, Inc. Common Stock
$4.98
0.20 (4.18%)
▲
5d:
+14.48%
30d:
+16.63%
90d:
-11.86%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When AVIR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: AVIR is 7.3% above its trading range ($4.64). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: AVIR is 7.3% above its trading range ($4.64). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: AVIR is currently trading at $4.98, which is considered extended relative to its 30-day fair value range of $4.28 to $4.64.
Technical Outlook: Technically, AVIR is in a downtrend. The price is approaching resistance at $5.04. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.2% recently.
Market Sentiment: AVIR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.67 (+74.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AVIR is in a downtrend. The price is approaching resistance at $5.04. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.2% recently.
Market Sentiment: AVIR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.67 (+74.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.28 -
$4.64
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+7.3% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.2%)
- BULLISH: Trading 74.0% below Wall St target ($8.67)
- CAUTION: Extended 7.3% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$4.28 -
$4.64
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.23
Resistance Level
$5.04
Current Trend
Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.60
Wall Street Target
$8.67
(+74.0%)
Revenue Growth (YoY)
295.2%
Earnings Growth (YoY)
264.1%
Share & Embed Analysis
Last updated: July 03, 2026 5:13 PM ET
Data refreshes hourly during market hours. Next update: 6:13 PM
Data refreshes hourly during market hours. Next update: 6:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AVIR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 67 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |